
Kazia Therapeutics (KZIA) Stock Forecast & Price Target
Kazia Therapeutics (KZIA) Analyst Ratings
Bulls say
Kazia Therapeutics is attractive because paxalisib targets a clinically validated PI3K/AKT/mTOR pathway with a differentiated oral, brain-penetrant profile that could matter in CNS-involved cancers where many competitors fall short. Early clinical signals are compelling, including an 83% ORR in frontline TNBC patients and meaningful biomarker evidence of reduced circulating tumor cell clusters and exhausted T cells, while broader programs in GBM, HR+/HER2- breast cancer, and pMMR CRC create multiple shots on goal. Financially, the company reported AU$69.5M in cash in FY 1H:26 and a modeled pro-forma AU$102M in FY 1H:27, which supports development runway and lowers near-term funding pressure.
Bears say
Kazia Therapeutics is weighed down by a weak clinical and regulatory foundation for paxalisib, since the GBM program did not meet the prespecified criteria to advance to Stage 2 and the FDA said the existing data were insufficient for an NDA, implying that substantially more evidence and capital are needed before any approval path is credible. The safety and efficacy profile also looks constraining, with common toxicities such as hyperglycemia, stomatitis, fatigue, and GI effects, plus a 46.7% discontinuation rate and 80% of patients requiring dose reductions or interruptions, while the observed OS benefit in newly diagnosed GBM was modest and recurrent disease data were worse than control. Commercially, the company faces a difficult, crowded oncology landscape where TNBC pathway inhibitors have repeatedly failed in Phase III, meaning Kazia must still prove paxalisib can differentiate itself enough to justify further financing, execution risk, and potential dilution.
This aggregate rating is based on analysts' research of Kazia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Kazia Therapeutics (KZIA) Analyst Forecast & Price Prediction
Start investing in Kazia Therapeutics (KZIA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kazia Therapeutics (KZIA) Forecast
Kazia Therapeutics (KZIA) Analyst Forecast & Price Prediction
Start investing in Kazia Therapeutics (KZIA)
Order type
Buy in
Order amount
Est. shares
0 shares